Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS) - Contact Levi & Korsinsky to Protect Your Rights Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws.
Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension. The Company had publicly characterized the PROSERA patient population as well-suited to demonstrate a treatment effect.
During the Q1 2025 earnings call on May 15, 2025, CEO Faheem Hasnain stated that baseline characteristics were "precisely what we have targeted" and that the Company was "more optimistic than ever about the likelihood of achieving positive results." Management also claimed "over 90% power given the sample size." The trial reached its planned enrollment target but the primary efficacy endpoint did not achieve the prespecified level of statistical significance.
If you suffered a loss on your Gossamer Bio, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289521
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS) - Contact Levi & Korsinsky to Protect Your Rights
2026-03-23 12:15 AM EDT
Securities Investigation: Levi & Korsinsky Investigates Disc Medicine, Inc. (IRON) on Behalf of Investors
2026-03-23 12:13 AM EDT
Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders
2026-03-23 12:11 AM EDT
Dec 16, 2025
What makes a press release rise above the rest? We analyzed the most successful press releases of 2025 to see what caught attention and why. This year’s review looks at total views from human readers and AI systems across the top five hundred public company press releases distributed through TMX Newsfile in 2025. These views come from all of Newsfile’s general distribution channels, such as Yahoo and Apple. They reflect how audiences discovered and engaged with each announcement. Key Insights...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services